- Home
- FRD vs ADVM Comparison
FRD vs ADVM Comparison
Compare FRD & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- ADVM
- Stock Information
- Founded
- FRD 1965
- ADVM 2006
- Country
- FRD United States
- ADVM United States
- Employees
- FRD N/A
- ADVM N/A
- Industry
- FRD Steel/Iron Ore
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRD Industrials
- ADVM Health Care
- Exchange
- FRD Nasdaq
- ADVM Nasdaq
- Market Cap
- FRD 122.0M
- ADVM 98.0M
- IPO Year
- FRD N/A
- ADVM 2014
- Fundamental
- Price
- FRD $17.00
- ADVM $2.96
- Analyst Decision
- FRD
- ADVM Strong Buy
- Analyst Count
- FRD 0
- ADVM 6
- Target Price
- FRD N/A
- ADVM $25.83
- AVG Volume (30 Days)
- FRD 24.4K
- ADVM 202.0K
- Earning Date
- FRD 06-10-2025
- ADVM 04-15-2025
- Dividend Yield
- FRD 0.94%
- ADVM N/A
- EPS Growth
- FRD N/A
- ADVM N/A
- EPS
- FRD 0.81
- ADVM N/A
- Revenue
- FRD $447,616,000.00
- ADVM $1,000,000.00
- Revenue This Year
- FRD N/A
- ADVM $1,187.80
- Revenue Next Year
- FRD N/A
- ADVM N/A
- P/E Ratio
- FRD $20.62
- ADVM N/A
- Revenue Growth
- FRD N/A
- ADVM N/A
- 52 Week Low
- FRD $12.24
- ADVM $2.75
- 52 Week High
- FRD $19.47
- ADVM $11.87
- Technical
- Relative Strength Index (RSI)
- FRD 61.76
- ADVM 35.10
- Support Level
- FRD $14.26
- ADVM $2.72
- Resistance Level
- FRD $17.24
- ADVM $3.04
- Average True Range (ATR)
- FRD 1.02
- ADVM 0.41
- MACD
- FRD 0.31
- ADVM -0.09
- Stochastic Oscillator
- FRD 95.20
- ADVM 14.54
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.